CWS / August Krogh Seminar – University of Copenhagen

August Krogh Club > Calendar > 2015 > CWS / August Krogh Sem...

CWS / August Krogh Seminar

A new class of antidiabetics may be broad-spectrum Alzheimer’s disease therapeutics

v/ Konrad Talbot, PhD, Associate Professor of Neurosurgery, Cedars-Sinai Medical School, Los Angeles, California, U.S.A.


Among the great challenges of 21st century medicine is finding effective treatments for Alzheimer’s disease (AD), a neurodegenerative dementia whose prevalence is growing so rapidly that it threatens to overwhelm healthcare systems in a few decades. While clinical trials on conventional AD drug targets (Aβ and its synthetic enzymes) have failed, a very promising new target for treatment has emerged, namely brain insulin resistance. This abnormality alone can cause or promote many of the key pathological and cognitive features of AD.

Using a novel ex vivo stimulation method, our group has shown that insulin resistance is a common and profound feature in brains of AD cases even in the absence of diabetes. We have now discovered that insulin resistance is also advanced in brains of mild cognitive impairment (MCI) cases, which often progress to AD dementia, and that this abnormality can be substantially reduced in brains of both MCI and AD dementia cases with one or more of the antidiabetics known as incretin receptor agonists, including liraglutide and a dual incretin receptor agonist. Such drugs are already known to markedly reduce a broad spectrum of pathologies and cognitive deficits in animal models of AD. The speaker will discuss these discoveries and their potential to produce the first effective treatment of AD.

Relevant papers

Research profile

Dr. Talbot is a leader in the discovery of brain insulin resistance in Alzheimer's disease, its molecular basis, cognitive consequences, and potential treatment with a new class of antidiabetics, which may provide the first effective treatment of Alzheimer's disease in general.

Furthermore, Dr. Talbot has contributed in the discovery of reduced dysbindin-1 in schizophrenia and its contributions to cognitive deficits in that disorder.


20 April 2015

14:30-15:30: Seminar and discussion
15:30-16:00: Post seminar servings and socializing


Auditorium 1, August Krogh Building, Universitetsparken 13, DK-2100 Copenhagen


Participation is free, but please register here.

For PhD students

PhD students participating in August Krogh seminars receive 0,2 ECTS per seminar


Christian Frøsig,, mobile +45 2875 1617

Upcoming seminars

Link to other upcoming seminars.